RxDoctor Payments Data

Frances Maniscalco

Nurse Practitioner · Paoli, PANPI 1568960821

Payments from drug & device makers

$814in general payments, 2019–2025

Across 15 payments — averaging $54.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$301
  • AstraZeneca$138
  • Amgen$125
  • Merck$111
  • Heartflow, Inc.$79
  • E.r. Squibb & Sons, L.L.C.$22
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$814100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$814 in reported general payments places this provider in the 80th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$6,406
Medicare patients
165
Services billed
227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$68,056
FarxigaDapagliflozin Propanediol12$8,759
Valsartan65$1,823
Metoprolol Succinate95$1,771
Rosuvastatin Calcium89$1,368
Losartan Potassium85$1,187
Atorvastatin Calcium70$955
Olmesartan Medoxomil30$720
Amlodipine Besylate165$709
Ezetimibe31$642
Flecainide Acetate15$554
Doxazosin Mesylate22$501
Potassium Chloride20$327
Hydrochlorothiazide88$311
Lisinopril38$298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$138$8,75912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Paoli

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →